Unmasking differential effects of rosiglitazone and pioglitazone in the combination treatment with n-3 fatty acids in mice fed a high-fat diet

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Kus, Vladimir ^a   Flachs, Pavel ^a   Kuda, Ondrej ^a   Bardova, Kristina ^a   Janovska, Petra ^a   Svobodova, Michaela ^a   Jilkova, Zuzana Macek ^a   Rossmeisl, Martin ^a   Wang Sattler, Rui ^b   Yu, Zhonghao ^b   Illig, Thomas ^b   Kopecky, Jan ^a  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CORN OIL; LIPID; OMEGA 3 FATTY ACID; PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; FATTY ACID OXIDATION; FATTY LIVER; GLUCOSE HOMEOSTASIS; INSULIN RESISTANCE; LIPID BLOOD LEVEL; LIPID DIET; MALE; METABOLITE; METABOLOMICS; MOUSE; NONHUMAN; OBESITY; ANIMAL; BLOOD; C57BL MOUSE; FAT INTAKE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS;

MUS; ZEA MAYS;

ANIMALS; BLOOD GLUCOSE; DIETARY FATS; FATTY ACIDS, OMEGA-3; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; METABOLOMICS; MICE; MICE, INBRED C57BL; OBESITY; THIAZOLIDINEDIONES;

EID: 80455125921     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027126     Document Type: Article

References (61)

1. Galgani JE, Moro C, Ravussin E, (2008) Metabolic flexibility and insulin resistance. Am J Physiol Endocrinol Metab 295: E1009-E1017.
2. Kopelman PG, (2000) Obesity as a medical problem. Nature 404: 635-643.
3. Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, et al. (2010) Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin 26: 907-915.
4. Reyes-Soffer G, Rondon-Clavo C, Ginsberg HN, (2011) Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opin Pharmacother 12: 1429-1438.
5. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, et al. (2008) Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Update regarding the thiazolidinediones. Diabetologia 51: 8-11.
6. Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, et al. (1997) Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46: 701-710.
7. Bell DS, Al Badarin F, O'Keefe JH Jr, (2011) Therapies for diabetic dyslipidaemia. Diabetes Obes Metab 13: 313-325.
8. Loke YK, Kwok CS, Singh S, (2011) Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 342: d1309.
9. Yang X, Smith U, (2007) Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia 50: 1127-1139.
10. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, et al. (2005) A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28: 1547-1554.
11. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, et al. (2007) Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30: 2458-2464.
12. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, et al. (2011) Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34: 916-922.
13. Whitehead JP, (2011) Diabetes: New conductors for the peroxisome proliferator-activated receptor gamma (PPARgamma) orchestra. Int J Biochem Cell Biol 43: 1071-1074.
14. Wilson-Fritch L, Nicoloro S, Chouinard M, Lazar MA, Chui PC, et al. (2004) Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114: 1281-1289.
15. Kim H, Haluzik M, Gavrilova O, Yakar S, Portas J, et al. (2004) Thiazolidinediones improve insulin sensitivity in adipose tissue and reduce the hyperlipidaemia without affecting the hyperglycaemia in a transgenic model of type 2 diabetes. Diabetologia 47: 2215-2225.
16. Wang P, Renes J, Bouwman F, Bunschoten A, Mariman E, et al. (2007) Absence of an adipogenic effect of rosiglitazone on mature 3T3-L1 adipocytes: increase of lipid catabolism and reduction of adipokine expression. Diabetologia 50: 654-665.
17. Higashi Y, Holder K, Delafontaine P, (2010) Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway. J Biol Chem 285: 36361-36368.
18. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, et al. (2001) Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108: 1001-1013.
19. Yang KJ, Noh JR, Kim YH, Gang GT, Hwang JH, et al. (2010) Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice. LIFE Sci 87: 405-410.
20. Kuda O, Stankova B, Tvrzicka E, Hensler M, Jelenik T, et al. (2009) Prominent role of liver in elevated plasma palmitooleate levels in response to rosiglitazone in mice fed high-fat diet. J Physiol Pharmacol 60: 135-140.
21. Kuda O, Jelenik T, Jilkova Z, Flachs P, Rossmeisl M, et al. (2009) n-3 Fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. Diabetologia 52: 941-951.
22. Djaouti L, Jourdan T, Demizieux L, Chevrot M, Gresti J, et al. (2010) Different effects of pioglitazone and rosiglitazone on lipid metabolism in mouse cultured liver explants. Diabetes Metab Res Rev 26: 297-305.
23. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR, et al. (2003) Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab 285: E354-E362.
24. Rabol R, Boushel R, Almdal T, Hansen CN, Ploug T, et al. (2010) Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetes Obes Metab 12: 806-814.
25. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, et al. (2007) Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ 334: 299.
26. Nettleton JA, Katz R, (2005) n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J Am Diet Assoc 105: 428-440.
27. Ruxton CH, Reed SC, Simpson MJ, Millington KJ, (2007) The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Diet 17: 449-459.
28. Riserus U, Willett WC, Hu FB, (2009) Dietary fats and prevention of type 2 diabetes. Prog Lipid Res 48: 44-51.
29. Kromhout D, Giltay EJ, Geleijnse JM, (2010) n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 363: 2015-2026.
30. Kunesova M, Braunerova R, Hlavaty P, Tvrzicka E, Stankova B, et al. (2006) The influence of n-3 polyunsaturated fatty acids and very low calorie diet during a short-term weight reducing regimen on weight loss and serum fatty acid composition in severely obese women. Physiol Res 55: 63-72.
31. Fasching P, Ratheiser K, Waldhausl W, Rohac M, Osterrode W, et al. (1991) Metabolic effects of fish-oil supplementation in patients with impaired glucose tolerance. Diabetes 40: 583-589.
32. Pelikanova T, Kohout M, Valek J, Kazdova L, Base J, (1993) Metabolic effects of omega-3 fatty acids in type 2 (non-insulin-dependent) diabetic patients. Ann N Y Acad Sci 683: 272-278.
33. Storlien LH, Kraegen EW, Chisholm DJ, Ford GL, Bruce DG, et al. (1987) Fish oil prevents insulin resistance induced by high-fat feeding in rats. Science 237: 885-888.
34. Jucker BM, Cline GW, Barucci N, Shulman GI, (1999) Differential effects of safflower oil versus fish oil feeding on insulin-stimulated glycogen synthesis, glycolysis, and pyruvate dehydrogenase flux in skeletal muscle: a 13C nuclear magnetic resonance study. Diabetes 48: 134-140.
35. Flachs P, Mohamed-Ali V, Horakova O, Rossmeisl M, Hosseinzadeh-Attar MJ, et al. (2006) Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed high-fat diet. Diabetologia 49: 394-397.
36. Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, et al. (2006) Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 55: 924-928.
37. Jelenik T, Rossmeisl M, Kuda O, Jilkova ZM, Medrikova D, et al. (2010) AMP-activated protein kinase alpha2 subunit is required for the preservation of hepatic insulin sensitivity by n-3 polyunsaturated fatty acids. Diabetes 59: 2737-2746.
38. Flachs P, Ruhl R, Hensler M, Janovská P, Zouhar P, et al. (2011) Synergistic induction of lipid catabolism and anti-inflammatory lipids in white fat of dietary obese mice in response to calorie restriction and n-3 fatty acids. Diabetologia 54: 2626-2638.
39. Ikemoto S, Takahashi M, Tsunoda N, Maruyama K, Itakura H, et al. (1996) High-fat diet-induced hyperglycemia and obesity in mice: Differential effects of dietary oils. Metabolism 45: 1539-1546.
40. Ruzickova J, Rossmeisl M, Prazak T, Flachs P, Sponarova J, et al. (2004) Omega-3 PUFA of marine origin limit diet-induced obesity in mice by reducing cellularity of adipose tissue. Lipids 39: 1177-1185.
41. Flachs P, Horakova O, Brauner P, Rossmeisl M, Pecina P, et al. (2005) Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce beta-oxidation in white fat. Diabetologia 48: 2365-2375.
42. Todoric J, Loffler M, Huber J, Bilban M, Reimers M, et al. (2006) Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 49: 2109-2119.
43. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, et al. (2010) GPR120 Is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687-698.
44. Libby P, Plutzky J, (2007) Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 99: 27B-40B.
45. Saravanan P, Davidson NC, Schmidt EB, Calder PC, (2010) Cardiovascular effects of marine omega-3 fatty acids. Lancet 376: 540-550.
46. Jump DB, (2004) Fatty acid regulation of gene transcription. Crit Rev Clin Lab Sci 41: 41-78.
47. Madsen L, Petersen RK, Kristiansen K, (2005) Regulation of adipocyte differentiation and function by polyunsaturated fatty acids. Biochim Biophys Acta 1740: 266-286.
48. Serhan CN, (2005) Novel omega-3-derived local mediators in anti-inflammation and resolution. Pharmacol Ther 105: 7-21.
49. van Schothorst EM, Flachs P, Franssen-van Hal NL, Kuda O, Bunschoten A, et al. (2009) Induction of lipid oxidation by polyunsaturated fatty acids of marine origin in small intestine of mice fed a high-fat diet. BMC Genomics 10: 110.
50. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, et al. (2008) Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7: 45-56.
51. Pietilainen KH, Sysi-Aho M, Rissanen A, Seppanen-Laakso T, Yki-Jarvinen H, et al. (2007) Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects--a monozygotic twin study. PLoS ONE 2: e218.
52. Lankinen M, Schwab U, Erkkila A, Seppanen-Laakso T, Hannila ML, et al. (2009) Fatty fish intake decreases lipids related to inflammation and insulin signaling-a lipidomics approach. PLoS ONE 4: e5258.
53. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, et al. (2010) Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 18: 1695-1700.
54. Lehmann R, Zhao X, Weigert C, Simon P, Fehrenbach E, et al. (2010) Medium chain acylcarnitines dominate the metabolite pattern in humans under moderate intensity exercise and support lipid oxidation. PLoS ONE 5: e11519.
55. Hallows WC, Yu W, Smith BC, Devries MK, Ellinger JJ, et al. (2011) Sirt3 promotes the urea cycle and fatty acid oxidation during dietary restriction. Mol Cell 41: 139-149.
56. Zhao X, Peter A, Fritsche J, Elcnerova M, Fritsche A, et al. (2009) Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? Am J Physiol Endocrinol Metab 296: E384-E393.
57. Huo T, Cai S, Lu X, Sha Y, Yu M, et al. (2009) Metabonomic study of biochemical changes in the serum of type 2 diabetes mellitus patients after the treatment of metformin hydrochloride. J Pharm Biomed Anal 49: 976-982.
58. Nawrocki AR, Rajala MW, Tomas E, Pajvani UB, Saha AK, et al. (2006) Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 281: 2654-2660.
59. Medrikova D, Macek JZ, Bardova K, Janovská P, Rossmeisl M et al, (2011) Sex differences during the course of diet-induced obesity in mice: adipose tissue expandability and glycemic control. Int J Obes doi:10.1038/ijo.2011.87.
60. Illig T, Gieger C, Zhai G, Romisch-Margl W, Wang-Sattler R, et al. (2010) A genome-wide perspective of genetic variation in human metabolism. Nat Genet 42: 137-141.
61. The Endocrine Society Statement to providers on the suspension of sales of pioglitazone by regulatory agencies in France and Germany (2011) Available: http://www.endo-society.org/advocacy/policy/upload/TES-Pioglitazone-Statement-Final.pdf Issued on June 13, 2011.